Last day of trading in BTA brought forward

The last day for trading in paid subscribed shares (BTA) (ISIN SE0006593885) on
Nasdaq Stockholm has been brought forward to February 16, 2015. The new shares
created through conversion of the BTAs will commence trading on Nasdaq Stockholm
as from February 18, 2015.

For further information:

Scott Myers, Chief Executive Officer, Aerocrine AB, Phone: +1 970 368 0336 or
+46 768 788 379

Marshall Woodworth, Chief Financial Officer, Aerocrine AB: +1 919 749 8748 or
+46 709 695 219

Or visit www.aerocrine.com

About Aerocrine

Aerocrine AB is a medical products company focused on the improved management
and care of patients with inflammatory airway diseases. As the pioneer and
leader in technology to monitor and manage airway inflammation, Aerocrine
markets NIOX MINO® and NIOX VERO®. Both products enable fast and reliable
management of airway inflammation and may therefore play a critical role in more
effective diagnosis, treatment and follow-up of patients with inflammatory
airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries
in the U.S., Germany, Switzerland and the U.K. Aerocrine shares were listed on
the Stockholm Stock Exchange in 2007.

+-----------------------------------------------------------------------------+
|Aerocrine is required to disclose the information provided herein pursuant to|
|the Securities Markets Act and/or the Financial Instruments Trading Act. The |
|information was submitted for publication at 8:00 a.m. on February 12, 2015. |
+-----------------------------------------------------------------------------+